Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.

AIDS (London, England) - 20 Aug 1998

Race E, Gilbert S M, Sheldon J G, Rose J S, Moffatt A R, Sitbon G, Dissanayeke S R, Cammack N, Duncan I B

Abstract excerpt

OBJECTIVES: Assessment of genotypic change in HIV protease during treatment with saquinavir (SQV) in combination with zidovudine (ZDV) and/or zalcitabine (ddC), to determine the influence of such changes on viral phenotype and response to treatment. DESIGN: Virologic substudies of Phase III clinical trials NV14256 and SV14604. METHODS: Population sequencing of HIV protease genes amplified from pre- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Microbial

Share to Genotype

Share to Molecular Sequence Data

Share to Mutation

Share to Phenotype

Share to RNA, Viral

Source

Identifiers

PMID: 9727567
DOI: 10.1097/00002030-199812000-00008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.PMID 9727567Read ↗

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.Semantic proximity Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.Semantic proximity Read ↗

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.Semantic proximity Read ↗

Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.Semantic proximity Read ↗

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.Semantic proximity Read ↗

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.Semantic proximity Read ↗

Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistanceSemantic proximity Read ↗

Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.Semantic proximity Read ↗

Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.Semantic proximity Read ↗

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.Semantic proximity Read ↗

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.